Rivia receives 3 million euros in seed capital

Zurich – Rivia has secured early financing in the amount of EUR 3 million. The ICT start-up based in Technopark Zurich will use this to further develop its platform for biotech companies. The Software-as-a-Service allows them to analyze clinical drug trials from one location.

ICT start-up Rivia has announced that it has raised 3 million euros in a seed financing round. The round was led by the Viennese venture capital firm Speedinvest. Amino Collective from Berlin and Nina Capital from Barcelona also took part.

The young company based in Technopark Zurich intends to use this start-up capital to expand its technical and customer service teams. In addition, the development of its cloud platform for biotech companies is to be driven forward. In this way, Rivia intends to fully exploit the potential of integrated study data and strengthen the positioning of its product as the platform where all data from clinical biopharma studies converge and are analyzed.

Founded in 2022 by biopharma professionals, the company offers a user-friendly software-as-a-service that addresses a key inefficiency in the industry, according to a statement from start-up promoter Venture Kick: While data collection methods have evolved, system integration capabilities and web application usability have not kept pace. As a result, the data remained fragmented and the visualization tools were outdated.

Rivia fills this gap and enables biotech companies to analyze study data more effectively. This should lead to a faster and more efficient market launch of their therapies. "This year," CEO and co-founder Erik Scalfaro told the online magazine EU-Startups, "we are introducing AI-supported analyses and AI-supported workflows to improve interaction with data." ce/mm

View full article